Model for end-stage liver disease scores in veno-arterial extracorporeal membrane oxygenation.


Journal

The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 27 2 2020
medline: 10 2 2021
entrez: 27 2 2020
Statut: ppublish

Résumé

Veno-arterial extracorporeal membrane oxygenation is a valuable therapeutic approach in patients with severe heart failure due to different etiologies. Current prognosis with veno-arterial extracorporeal membrane oxygenation is unsatisfactory, and the risk stratification is still challenging. Therefore, we aimed to evaluate the predictive value of different baseline model for end-stage liver disease scores for survival in patients with veno-arterial extracorporeal membrane oxygenation. We conducted an observational, retrospective study of consecutive veno-arterial extracorporeal membrane oxygenation-treated patients between January 2012 and August 2018. The four types of model for end-stage liver disease scores-model for end-stage liver disease, international normalized ratio-excluded model for end-stage liver disease, modified model for end-stage liver disease, and model for end-stage liver disease with sodium-were calculated preoperatively. Veno-arterial extracorporeal membrane oxygenation was used based on the four clinical indications: primer graft failure after heart transplantation, weaning failure from cardiopulmonary bypass, acute myocardial infarction with refractory cardiogenic shock, and bridge to transplantation or bridge to candidacy. The primary endpoint of the study was overall mortality. The secondary endpoint was in-hospital mortality. We performed univariable and multivariable Cox regression analyses. Data from 135 patients were analyzed. The median follow-up was 952 days (interquartile range = 417-1555 days). In-hospital mortality was 62.2%, and overall mortality was 71.1%. The multivariable Cox regression analysis is adjusted for indication, and the survival after veno-arterial extracorporeal membrane oxygenation score showed that the following scores were associated with overall mortality: model for end-stage liver disease (hazard ratio = 1.04; 95% confidence interval = 1.01-1.07; Model for end-stage liver disease, modified model for end-stage liver disease, and model for end-stage liver disease with sodium scores could be useful in the risk stratification of veno-arterial extracorporeal membrane oxygenation treatment in varying clinical indications.

Identifiants

pubmed: 32098569
doi: 10.1177/0391398820906538
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

684-691

Auteurs

Ádám Nagy (Á)

Károly Rácz School of PhD Studies, Semmelweis University, Budapest, Hungary.

Enikő Holndonner-Kirst (E)

Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.

Csaba Eke (C)

Károly Rácz School of PhD Studies, Semmelweis University, Budapest, Hungary.

Miklós D Kertai (MD)

Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.

Levente Fazekas (L)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Kálmán Benke (K)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Miklós Pólos (M)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Zoltán Szabolcs (Z)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

István Hartyánszky (I)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

János Gál (J)

Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.

Béla Merkely (B)

Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Andrea Székely (A)

Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH